PITAVASTATIN MAGNESIUM — Competitive Intelligence Brief

PITAVASTATIN MAGNESIUM (PITAVASTATIN MAGNESIUM) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: HMG-CoA Reductase Inhibitor [EPC].

marketed HMG-CoA Reductase Inhibitor [EPC] 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase Small molecule

Target snapshot

PITAVASTATIN MAGNESIUM (PITAVASTATIN MAGNESIUM). Pitavastatin inhibits HMG-CoA reductase, reducing cholesterol synthesis and increasing LDL uptake by the liver.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PITAVASTATIN MAGNESIUM TARGET	PITAVASTATIN MAGNESIUM		marketed	HMG-CoA Reductase Inhibitor [EPC]	3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase	2017-01-01
Livalo	PITAVASTATIN	Kowa Co	marketed	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	2009-01-01
Crestor	rosuvastatin	AstraZeneca	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	2003-01-01
Zetia	EZETIMIBE	Merck & Co.	marketed	HMG-CoA Reductase Inhibitor [EPC]	Niemann-Pick C1-like protein 1	2002-01-01
Lipitor	atorvastatin	Pfizer Inc.	marketed	HMG-CoA reductase inhibitor (statin)	HMG-CoA reductase	1996-12-17
Lescol	FLUVASTATIN	Novartis	marketed	HMG-CoA Reductase Inhibitor	HMG-CoA reductase	1993-01-01
Mevacor	LOVASTATIN	Merck & Co.	marketed	HMG-CoA Reductase Inhibitor	3-hydroxy-3-methylglutaryl-coenzyme A reductase	1987-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2037-06-07 — Lipitor · 11654106 · US
• 2037-06-07 — Lipitor · 11369567 · US

Sponsor landscape (HMG-CoA Reductase Inhibitor [EPC] class)

1. Merck & Co. · 2 drugs in this class
2. · 1 drug in this class